OncoCyte Corporation – NASDAQ:OCX
OncoCyte stock price today
$3.17
+1.06
+50.24%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
OncoCyte stock price monthly change
-36.64%
month
OncoCyte stock price quarterly change
-36.64%
quarter
OncoCyte stock price yearly change
-15.60%
year
OncoCyte key metrics
Market Cap | 37.37M |
Enterprise value | 11.69M |
P/E | -1.98 |
EV/Sales | 1.44 |
EV/EBITDA | -0.19 |
Price/Sales | 4.93 |
Price/Book | 0.52 |
PEG ratio | 0.03 |
EPS | -24.43 |
Revenue | 1.38M |
EBITDA | -8.30M |
Income | -39.94M |
Revenue Q/Q | -40.74% |
Revenue Y/Y | N/A |
Profit margin | -788.06% |
Oper. margin | -782.49% |
Gross margin | -8.05% |
EBIT margin | -782.49% |
EBITDA margin | -601.09% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOncoCyte stock price history
OncoCyte stock forecast
OncoCyte financial statements
| Jun 2023 | 463K | -8.33M | -1799.78% |
|---|---|---|---|
| Sep 2023 | 429K | -6.48M | -1512.59% |
| Dec 2023 | 314K | -15.99M | -5092.99% |
| Mar 2024 | 176K | -9.12M | -5186.93% |
| Sep 2025 | 1.46M | -3.33M | -228.2% |
|---|---|---|---|
| Dec 2025 | 2.85M | -4.64M | -163.08% |
| Dec 2025 | 1.76M | -3.38M | -191.7% |
| Mar 2026 | 2.28M | -3.08M | -135.14% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 87540000 | 43.94M | 50.19% |
|---|---|---|---|
| Sep 2023 | 81587000 | 44.02M | 53.96% |
| Dec 2023 | 74892000 | 49.29M | 65.83% |
| Mar 2024 | 70973000 | 54.05M | 76.16% |
| Jun 2023 | -6.83M | 123K | 12.27M |
|---|---|---|---|
| Sep 2023 | -2.25M | -1.29M | -30K |
| Dec 2023 | -4.56M | 241K | -30K |
| Mar 2024 | -3.83M | -24K | 0 |
OncoCyte alternative data
| Aug 2023 | 75 |
|---|---|
| Sep 2023 | 75 |
| Oct 2023 | 75 |
| Nov 2023 | 75 |
| Dec 2023 | 75 |
| Jan 2024 | 75 |
| Feb 2024 | 75 |
| Mar 2024 | 75 |
| Apr 2024 | 75 |
| May 2024 | 43 |
| Jun 2024 | 43 |
| Jul 2024 | 43 |
OncoCyte other data
100.00%
0.00%
of OCX is owned by hedge funds
34
-23
34.75M
-26.00M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 2457288 | 0 |
| Oct 2024 | 1349009 | 0 |
| Dec 2024 | 122719 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ARNO ANDREW director | Common Stock, no par value | 12,500 | $2.11 | $26,350 | ||
Purchase | SMITH PATRICK W 10 percent owner | Common Stock, no par value | 90,219 | $2.13 | $192,166 | ||
Purchase | JAMES ANDREA S. officer: Chief Financial Officer | Common Stock, no par value | 20,000 | $2.29 | $45,800 | ||
Purchase | JAMES ANDREA S. officer: Chief Financial Officer | Common Stock, no par value | 33,670 | $2.97 | $100,000 | ||
Purchase | BROADWOOD PARTNERS, L.P. 10 percent owner | Common Stock, no par value | 1,315,339 | $1.47 | $1,938,810 | ||
Purchase | BROADWOOD PARTNERS, L.P. 10 percent owner | Common Stock, no par value | 2,420,000 | $1.46 | $3,528,360 | ||
Purchase | RIGGS JOSH director, officer: CEO and Pres.. | Common Stock, no par value | 3,390 | $2.95 | $10,001 | ||
Purchase | ARNO ANDREW director | Common Stock, no par value | 33,898 | $2.95 | $99,999 | ||
Purchase | KINGSLEY ALFRED D director | Common Stock, no par value | 30,000 | $0.22 | $6,450 | ||
Purchase | PURA VIDA INVESTMENTS, LLC 10 percent owner | Common Stock | 663,000 | $0.3 | $200,226 |
| Quarter | Transcript |
|---|---|
| Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 12 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Ronald A. Andrews Jr. (1960) Chief Executive Officer, Pres & Director | $978,350 |
-
What's the price of OncoCyte stock today?
One share of OncoCyte stock can currently be purchased for approximately $3.17.
-
When is OncoCyte's next earnings date?
Unfortunately, OncoCyte's (OCX) next earnings date is currently unknown.
-
Does OncoCyte pay dividends?
No, OncoCyte does not pay dividends.
-
How much money does OncoCyte make?
OncoCyte has a market capitalization of 37.37M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 56.89% to 1.5M US dollars.
-
What is OncoCyte's stock symbol?
OncoCyte Corporation is traded on the NASDAQ under the ticker symbol "OCX".
-
What is OncoCyte's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of OncoCyte?
Shares of OncoCyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are OncoCyte's key executives?
OncoCyte's management team includes the following people:
- Mr. Ronald A. Andrews Jr. Chief Executive Officer, Pres & Director(age: 65, pay: $978,350)
-
How many employees does OncoCyte have?
As Jul 2024, OncoCyte employs 43 workers, which is 43% less then previous quarter.
-
When OncoCyte went public?
OncoCyte Corporation is publicly traded company for more then 9 years since IPO on 30 Dec 2015.
-
What is OncoCyte's official website?
The official website for OncoCyte is oncocyte.com.
-
Where are OncoCyte's headquarters?
OncoCyte is headquartered at 15 Cushing, Irvine, CA.
-
How can i contact OncoCyte?
OncoCyte's mailing address is 15 Cushing, Irvine, CA and company can be reached via phone at +94 94097600.
OncoCyte company profile:
OncoCyte Corporation
oncocyte.comExchange:
NASDAQ
Full time employees:
43
Industry:
Biotechnology
Sector:
Healthcare
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
15 Cushing
Irvine, CA 92618
Irvine, CA 92618
CIK: 0001642380
ISIN: US68235C2061
CUSIP: 68235C107
